期刊文献+

人源性抗HBc单链抗体真核表达载体的构建及其细胞内表达 被引量:1

Construction of human anti-HBc ScFv eukaryotic expression vector and expression of anti-HBc ScFv in HepG2 cells
下载PDF
导出
摘要 目的构建人源性抗HBc单链抗体的真核表达载体并在细胞内表达。方法采用DNA重组技术将特异性人源性抗HBc单链抗体基因插入真核表达载体pEGFP-c1;转染HepG2细胞,经G418筛选细胞,荧光倒置显微镜观察细胞内抗HBc单链抗体与绿色荧光蛋白融合表达情况,并用ELISA法检测HBc单链抗体基因的细胞内表达。结果成功地构建了人源性抗HBc单链抗体的真核表达载体。转染HepG2细胞并筛选后,经荧光倒置显微镜观察,细胞内有绿色荧光蛋白表达;ELISA检测细胞内表达的单链抗体片段具有HBcAg结合活性。结论人源性抗HBc单链抗体的真核表达载体的构建并在细胞内成功表达,为胞内抗HBc单链抗体的进一步研究奠定了基础。 AIM: To construct an eukaryotic expression vector of human single-chain variable fragment ~against hepatitis B virus core protein (anti-HBc ScFv) and detect its expression in HepG2 cells. METHODS: Anti-HBc ScFv genes were amplified from the plasmids abstracted from positive clone and inserted into pEGFP-c1 vector that contained green fluorescent protein gene. The recombinant plasmids were transfected into HepG2 cells, and resistant clones were obtained by G418 selection. The expression of the gene of fusion protein was determined by fluorescent invert microscope and ELISA. RESULTS: Recombinant plasmids were successfully constructed. The plasmid transfected HepG2 cells were obtained by G418 selection. Specific fluorescence was observed in HepG2 cells 48 hours after transfection. ELISA analysis confirmed the expression of anti-HBc ScFv in the cells. CONCLUSION: The construction of human anti-HBc ScFv eukaryotic expression vector and its expression in HepG2 cells lay the foundation for advanced research of intracellular anti-HBc ScFv.
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2005年第5期915-918,共4页 Chinese Journal of Pathophysiology
关键词 肝炎核心蛋白 乙型 基因表达 HEPG2细胞 Hepatitis B virus core proteins Gene expression HepG2 cells
  • 相关文献

参考文献9

  • 1高辉,杨安钢,高磊,任向荣,余宙耀.人源性抗HBsAg抗体Fab段噬菌体呈现文库的构建、筛选及阳性克隆核苷酸序列测定[J].中国病理生理杂志,2001,17(4):308-311. 被引量:6
  • 2萨姆布鲁克J 弗里奇F 曼尼阿蒂 金冬雁 黎孟枫 译.分子克隆实验指南(第2版)[M].北京:科学出版社,1996..
  • 3Rondon IJ, Marasco WA. Intracellular antibodies (intrabodies) for gene therapy of infectious diseases[J]. Annu Rev Microbiol, 1997, 51: 257-283.
  • 4Visintin M, Tse E, Axelson H, et al. Selection of antibodies for intracellular function using a two-hybrid in vivo system[J]. Proc Natl Acad Sci USA, 1999, 96(21): 11723-11728.
  • 5Tewari D, Goldstein SL, Notkins AL, et al. cDNA encoding a single-chain antibody to HIV p17 with cytoplasmic or nuclear retention signals inhibits HIV-1 replication[J]. J Immunol, 1998, 161(5): 2642-2647.
  • 6Alvarez RD, Barnes MN, Gomez-Navarro J, et al. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial[J]. Clin Cancer Res, 2000, 6(8): 3081-3087.
  • 7汤正好.基因工程单链抗体在传染病中的应用研究进展[J].国外医学(流行病学.传染病学分册),2002,29(3):135-138. 被引量:6
  • 8乔旭刚,Unch.,ZH.用细胞筛选噬菌体抗体库分离自然杀伤细胞抑制受体的单链抗体[J].中国病理生理杂志,1998,14(5):500-503. 被引量:2
  • 9Hoogenboom HR, Griffiths AD, Johnson KS, et al. Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains[J]. Nucleic Acids Res, 1991, 19(15): 4133-4137.

二级参考文献23

共引文献24

同被引文献10

  • 1Hombach A,Wieczarkowiecz A,Marquardt T,et al.Tumor-specific T cell activation by recombinant immunoreceptors:CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule[J].J Immunol,2001,167(11):6123-6131.
  • 2Jensen M,Tan G,Forman S,et al.CD20 is a molecular target for scFvFc:zeta receptor redirected T cells:implications for cellular immunotherapy of CD20+ malignancy[J].Biol Blood Marrow Transplant,1998,4(2):75-83.
  • 3Jensen MC,Cooper LJ,Wu AM,et al.Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy[J].Cytotherapy,2003,5(2):131-138.
  • 4Wang J,Press OW,Lindgren CG,et al.Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8^+ cytotoxic T lymphocytes[J].Mol Ther,2004,9(4):577-586.
  • 5萨姆布鲁克,E.F.弗里奇,T.曼尼阿蒂斯.分子克隆实验指南[M].北京:科学出版社,1999.237-262.
  • 6Cheadle EJ,Gilham DE,Thistlethwaite FC,et al.Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells[J].Br J Haematol,2005,129(3):322-332.
  • 7Dall P,Herrmann I,Durst B,et al.In vivo cervical cancer growth inhibition by genetically engineered cytotoxic T cells[J].Cancer Immunol Immunother,2005,54(1):51-60.
  • 8Schirrmann T,Pecher G.Specific targeting of CD33(+) leukemia cells by a natural killer cell line modified with a chimeric receptor[J].Leuk Res,2005,29(3):301-306.
  • 9Gonzalez S,Naranjo A,Serra no LM,et al.Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma[J].J Gene Med,2004,6(6):704-711.
  • 10高辉,杨安钢,高磊,任向荣,余宙耀.人源性抗HBsAg抗体Fab段噬菌体呈现文库的构建、筛选及阳性克隆核苷酸序列测定[J].中国病理生理杂志,2001,17(4):308-311. 被引量:6

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部